NCT06229665

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

Name: Clinical Trial NCT06229665
Creator: LumiThera, Inc.
Keywords: Dry Age-related Macular Degeneration, Valeda Light Delivery System, Phase 2/3, device, clinical trial, United States of America

An Open-Label, Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE IIIB)

LumiThera, Inc.·Phase 2/3·ClinicalTrials.gov·device·Device trialRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Dry Age-related Macular Degeneration
Drug/Device/Intervention: Valeda Light Delivery System
Study type: Interventional
Intervention type: device

Sponsor & location

Primary sponsor: LumiThera, Inc.
Location: Beverly Hills,Palo Alto,Altamonte Springs,Hagerstown,Cherry Hill,New York,Durham,McAllen,Silverdale, United States of America

Timeline & enrollment

Phase: Phase 2/3
Start date: Oct 25, 2023
End date: Jun 01, 2025
Enrollment: 75 participants

Primary outcome

Early Treatment Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA)

Summary

This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III study.

ICD-10 classifications

Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06229665
Type: Device Trial

About this record

Access comprehensive clinical trial information for NCT06229665 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by LumiThera, Inc. and is currently Recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 75 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.